Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2004 October;52(5) > Minerva Cardioangiologica 2004 October;52(5):349-64

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  INTERVENTIONAL CARDIOLOGY 

Minerva Cardioangiologica 2004 October;52(5):349-64

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English

Drug-eluting stents: from randomized trials to the real world

Saia F., Degertekin M., Lemos P. A., Serruys P. W.


PDF


Drug-eluting stents have been developed to prevent in-stent restenosis following percutaneous coronary revascularization. In a number of randomized trials, polymer-coated sirolimus- and paclitaxel-eluting stents have been proven to markedly reduce the incidence of angiographic restenosis and repeat revascularization when compared to bare metal stents. Effectiveness of sirolimus-eluting stents in the prevention of restenosis has been confirmed in many subsets of patients and lesions not included in randomized trials, such as in-stent restenosis, chronic total occlusion, acute myocardial infarction, and others. Very promising data in the real world are emerging for utilization of paclitaxel-eluting stents as well. Other drug-eluting stents gave less b

top of page